News|Articles|August 1, 2025
How One Neuro Brand Cut Through Prior Auth Barriers
Case study on how a neuro biologic brand leveraged SamaCare’s insights and interventions platform to decrease patient access friction and improve patient starts.
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5